Fibroblasts are the most common cells of connective tissue. They produce the fibrous protein called collagen. "The major source of fibrosis in SSc is over production of collagens from fibroblasts."(1) ISN. (Also see What is Scleroderma? and Causes of Scleroderma)
Fibroblasts. Fibroblasts provide a structural framework (stroma) for many tissues, and play a critical role in wound healing. They are the most common cells of connective tissue in animals. Wikipedia
Anti-elastase and anti-collagenase potential of Lactobacilli exopolysaccharides (LEPS) on human fibroblast. By consideration of high anti–collagenase, anti–elastase, antioxidant activity and wound healing of LEPS, they could be considered as good candidate of skin anti–aging agents for tissue engineering and skin regeneration scaffolds. PubMed, Artif Cells Nanomed Biotechnol, 2018 Feb 27:1-11. (Also see Wound Healing in Systemic Scleroderma)
Pushing cells to self–destruct combats deadly fibrosis. New research offers clues for how to selectively destroy the cells known as myofibroblasts that drive the condition. Science Magazine, 12/13/2017.
The Antiretroviral nelfinavir mesylate (NFV), a potential therapy for systemic scleroderma. NFV abrogates TGF–ß1–mediated myofibroblast differentiation and pulmonary fibrosis through off–target protein binding and supports consideration of this FDA–approved medication as an anti–fibrotic agent. PubMed, Arthritis Rheumatol, 09/21/2017. (Also see Treatments for Pulmonary Fibrosis)
Downregulation of Aquaporin3 in Systemic Sclerosis (SSc) Dermal Fibroblasts. SSc manifestations like skin dryness, abnormal wound healing, and fibrotic lesions may be related to downregulation of AQP3 in SSc fibroblasts. PubMed, Iran J Allergy Asthma Immunol, 2017 Jun;16(3):228-234.
The mighty fibroblast and its utility in scleroderma research. Fibroblasts have proven to be valuable tools in the search for effective anti–fibrotic therapies for fibrosis. Journal of Scleroderma and Related Disorders, JSRD 2017; 2(2): 100 - 107.
Unifying mechanism for different fibrotic diseases. Here, we demonstrate that many endstage fibrotic diseases converge in the activation of the Activator protein 1 transcription factor c-JUN in the pathologic fibroblasts. PubMed, Proc Natl Acad Sci U S A, 2017 May 2;114(18):4757-4762.
Innate Immunity in Systemic Sclerosis (SSc). Currently, no effective therapy exists and exploiting the innate immune system perturbation may be one possible avenue. Innate immune dysregulation is key in SSc pathogenesis and may represent a novel target. PubMed, Curr Rheumatol Rep, 2017 Jan;19(1):2.
Transforming growth factor beta (TGF–beta1), int/Wingless (WNT) and sonic hedgehog (SHH) signaling in tumor progression and in fibrotic diseases. In this review, we focus on TGF–beta, WNT and SHH signal transduction pathways and describe small molecule inhibitors that are used in phase I/II clinical trials to treat fibrosis or fibrotic cancers. PubMed, Front Biosci (Schol Ed), 2017 Jan 1;9:31-45.
Scleroderma (SSc) peripheral B lymphocytes secrete interleukin-6 and TGF–ß and activate fibroblasts. Peripheral B lymphocytes from SSc patients secreted IL-6 and TGF–ß, and activated fibroblasts in vitro. PubMed, Arthritis Rheumatol, 12/19/2016. (Also see Interleukins)
Bosentan and macitentan (ERA's) prevent the endothelial–to–mesenchymal transition (EndoMT) in systemic sclerosis: in vitro study. The present study provides further in vitro evidence of the use of ERA in inhibiting the EndoMT process, supporting the clinical efficacy of these drugs in SSc therapy and their usefulness for interfering with progressive fibrosis. PMC, Arthritis Res Ther, October 2016; 18: 228. (Also see Tracleer (Bosentan) and Macitentan (Opsumit™))
Expression of the endocannabinoid receptors in human fascial tissue. The endocannabinoid receptors of fascial fibroblasts can contribute to modulate the fascial fibrosis and inflammation. PubMed, Eur J Histochem, 2016 Jun 28;60(2):2643. (Also see Endocannabinoid System)
Mechanistic insight into the norepinephrine (NE)–induced fibrosis in systemic sclerosis (SSc). These results suggest that cold exposure and/or emotional stress–induced NE might contribute to the skin fibrosis via potentiation of IL-6 production from fibroblasts in SSc. PMC, Sci Rep, 2016; 6: 34012. (Also see Interleukins)
Tribbles homologue 3 stimulates canonical TGF-ß signalling to regulate fibroblast activation and tissue fibrosis. The present study characterises TRB3 as a novel profibrotic mediator in systemic sclerosis. PubMed, Ann Rheum Dis, 2016 Mar;75(3):609-16. (Also see Molecular Defect)
Toll–like receptor 9 (TLR9) signaling is augmented in systemic sclerosis (SSc) and elicits transforming growth factor–ß (TGF–ß)–dependent fibroblast activation. In patients with SSc, mitochondrialDNA and other damage–associated TLR9 ligands in the skin might trigger localized activation of TLR9 signaling, TGF–ß production and consequent fibroblast activation. PubMed, Arthritis Rheumatol, 03/04/2016.
Multiplex cytokine analysis of dermal interstitial blister fluid defines local disease mechanisms in systemic sclerosis (SSc). An immuno-inflammatory environment and aberrant vascular repair are intimately linked to fibroblast activation in lesional skin in SSc. Arthritis Research and Therapy, 03/23/2015.
A reactive oxygen species(ROS)-mediated loop maintains the increased expression of NOX2 and NOX4 in skin fibroblasts from patients with systemic sclerosis (SSc). NOX2 and NOX4 generate ROS in SSc fibroblasts and play a critical role in cell activation and DNA damage. PubMed, Arthritis Rheumatol, 02/23/2015.
Role of Cellular Senescence and NOX4-Mediated Oxidative Stress in Systemic Sclerosis (SSc) Pathogenesis. Numerous studies have implicated oxidative stress in SSc pathogenesis, suggesting a plausible mechanism in which excessive oxidative stress induces cellular senescence and that the molecular events play an important role in the fibrotic and fibroproliferative vasculopathy characteristic of SSc. PubMed, Curr Rheumatol Rep, 2015 Jan;17(1):473.
(1) Xiong M, Arnett FC, Guo X, Xiong H, Zhou X (2008) Differential Dynamic Properties of Scleroderma Fibroblasts in Response to Perturbation of Environmental Stimuli. PLoS ONE 3(2): e1693.
SCLERO.ORG is the world's leading nonprofit for trustworthy research, support, education and awareness for scleroderma and related illnesses.
We are a service of the nonprofit International Scleroderma Network (ISN), which is a 501(c)(3) U.S.-based public charitable foundation, established in 2002. Meet Our Team, or Volunteer. Donations may also be mailed to: